Q2 FY2026 EarningsQ2 FY26 results for CGEM.US showed a narrower-than-expected loss, with GAAP EPS of -$0.81 beating the -$0.80 consensus by $0.01. Operating expenses were significantly lower than anticipated, particularly in R&D, which fell 27.2% YoY to $44.4M. With a robust cash balance of $356M, the company extended its operational runway into 2029, while key clinical catalysts for CLN-978 and velinotamig remain on track for Q3 and Q4 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Cullinan Therapeutics(CGEM) the EBIT is -57.25 M (+24.47%), Miss estimate;the EPS is -0.81 (+24.3%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.06B24.47%
-0.06B25.18%
-0.00B0.71%
EPSMiss expectations
-0.8124.30%
-0.801625.09%
-0.00840.79%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf